Cambridge Healthtech Institute’s 13th annual two-part conference on Advances in Gene Editing and Gene Silencing will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies.
Part 2 will cover the latest in the use of CRISPR/Cas9 and RNAi for functional screening. It will cover everything from assay design to data analysis when conducting low and high throughput screens and generating cellular models, both in vitro and in vivo, using CRISPR/Cas9, siRNA (small interfering RNA), and shRNA (short hairpin RNA), in a way that will evoke thought-provoking discussions and sharing of best practices. Screening experts from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of these diverse screening platforms for a wide range of applications.
Differences Between CRISPR/RNAi Necessitate Re-Thinking Analysis Algorithms
Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health
Extracting Novel Insight from Genome-Scale Genetic Screens Through Integrated Iterative Analysis
Iain Fraser, Ph.D., Investigator, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Towards Combinatorial Drug Discovery: Mining Heterogenous Phenotypes from Large Scale RNAi/Drug Perturbations
Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
PANEL DISCUSSION: Strategies to Interpret and Prioritize Data from CRISPR and RNAi Screens
Moderator: Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health
CRISPR Libraries for Functional Genomics: Optimizing On-Target Activity and Avoiding Off-Target Effects
John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT
The Right Tool for the Job: Complementary Uses of RNAi and CRISPR in Drug Discovery
Jonathan Preall, Ph.D., Senior Scientist, Oncology Target Discovery Group, Pfizer, Inc.
Large Scale CRIPSR Screens for Discovery of Genotype Specific Combination Therapies
Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center
Immune Checkpoint Discovery Using RNAi Screens in Solid Tumors
Tillmann Michels, Head of Research Group, Immune Checkpoint Inhibitors, Department of Interventional Immunology, Regensburg Center for Interventional Immunology; Member, Department of Translational Immunology, German Cancer Research Center
CRISPR Mutagenesis Approach for Cancer Drug Target Identification
Junwei Shi, Ph.D., Assistant Professor, Department of Cancer Biology, University of Pennsylvania School of Medicine
Fas-Mediated Apoptosis Overcomes Resistance to Kras-Silencing in Lung Cancer Cells
Haiwei Mou, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Wen Xue, RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School
Applying Functional Genomics in Mouse Models of Human Cancer
Yejing Ge, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Elaine Fuchs, Department of Mammalian Cell Biology and Development, Rockefeller University
For questions or suggestions about the meeting, please contact:
Tanuja Koppal, Ph.D.
Cambridge Healthtech Institute
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483